^
Association details:
| Biomarker: | CTLA4 promoter hypomethylation |
|---|---|
| Cancer: | Clear Cell Renal Cell Carcinoma |
| Drug Class: | PD1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma
Excerpt:
...in multivariable Cox regression, CTLA4 promoter hypomethylation remained an independent predictor of improved outcome in ICB-treated ccRCC after co-adjustment of the International Metastatic Renal Cell Carcinoma Database Consortium score (HR 3.00 (95% CI 1.47 to 6.28), p=0.003).
DOI:
10.1136/jitc-2021-002949
